Amylyx appoints Camille Bedrosian as chief medical officer

Amylyx announced the appointment of Camille Bedrosian as chief medical officer, or CMO. In this role, Bedrosian will lead global functions in medical affairs, regulatory, safety and pharmacovigilance, biometrics, clinical development, and clinical operations. Bedrosian brings nearly 30 years of experience. Amylyx’ current CMO, Patrick Yeramian will stay on as an advisor through the end of the year and will then transition into retirement, as announced in December 2022.